Jacobio Pharmaceuticals Group's (HKG:1167) subsidiary Jacobio Pharmaceuticals received an upfront payment of 172.8 million yuan from Shanghai Allist Pharmaceuticals (SHA:688578) for the License-Out agreement between the parties, a Friday filing with the Hong Kong Exchange said.
The payment includes the upfront payment of 150 million yuan and partial payment for research and development expenses out of the total of 200 million yuan Jacobio is supposed to receive from Allist in the near term.
Jacobio Pharmaceuticals, the subsidiary, had entered into a license-out agreement for the R&D, manufacturing, and commercialization of its Glecirasib (JAB-21822) and JAB-3312 with Allist for the regions of China, Hong Kong, Macau, and Taiwan on Aug. 30.
The oncology therapies company's shares closed nearly 5% higher on Friday.
Price (HKD): $1.84, Change: $+0.080, Percent Change: +4.55%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。